Neurosense Therapeutics Ltd

Change company Symbol lookup

Select an option...

NRSN Neurosense Therapeutics Ltd

QLGN Qualigen Therapeutics Inc

JOFF JOFF Fintech Acquisition Corp

IR Ingersoll Rand Inc

TGT Target Corp

CCLP CSI Compressco LP

BIOT Biotech Acquisition Co

XNXNX Nuveen New York Select Tax Free Income Portfolio

DHHC DiamondHead Holdings Corp

WFC Wells Fargo & Co

Go

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update. (PR Newswire)

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian Medicines Agency (AIFA) to commence patient enrollment in...(PR Newswire)

-- NeuroSense Therapeutics receives FDA clearance to commence patient enrollment in the U.S. with PrimeC, a novel combination therapy -- Follows a successful U.S. pharmacokinetic (PK) study which confirmed PrimeC's favorable extended release...(PR Newswire)

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming...(PR Newswire)

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe(R) Partnering Conference on October 24-26, 2022 in Lepzing...(PR Newswire)

View the Nasdaq Opening Bell Ringing & CEO Message Here: LINK NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and released the video of...(PR Newswire)

Investors and analysts interested in participating in the Summit via webinar may register here: LINK NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced...(PR Newswire)

Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023 NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative...(PR Newswire)

-- Biomarker data to be presented provide indication of PrimeC's efficacy in ALS -- Phase IIb PARADIGM ALS trial's primary endpoints include biomarkers and ALS-related hallmarks -- Topline results expected H1 2023 (PR Newswire)

-- PrimeC is safe and tolerable at over 4x the maximal clinical dose -- Data support current Phase IIb PARADIGM study design, new PrimeC formulation, and potential favorable clinical trial outcome NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)...(PR Newswire)

-- Groundbreaking ALS biomarker research: Marks the first publication of NeuroSense's novel biomarker results demonstrating PrimeC's effect on ALS related hallmarks -- PrimeC showed a statistically significant impact on key disease-related...(PR Newswire)